Global Diclofenac Patches Market Size, Share and Trends Analysis Report, By Application (Lesions, Sprains, and Strains), and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Forecast (2022-2028)

The diclofenac patches market is anticipated to grow at a significant CAGR of 6.2% during the forecast period (2022-2028). Diclofenac is a nonsteroidal anti-inflammatory medicine (NSAID) that acts by decreasing inflammation and pain-causing hormones in the body. The most extensively utilized therapeutic family of analgesic chemicals is NSAIDs, which are authorized for use in alleviating post-extraction pain. Diclofenac sodium is a regularly prescribed NSAID with anti-inflammatory, analgesic, and antipyretic properties. Diclofenac transdermal patches are placed directly in the region of discomfort to provide brief relief from mild muscular and joint aches and pains. Due to its lower incidence of systemic side effects, transdermal diclofenac patches are more effective than diclofenac pills. The major factor driving the growth of the market includes the rising prevalence of chronic pain diseases. According to the CDC, in 2019, 20.4% of people reported chronic pain, and 7.4% of adults had chronic pain that often-hindered their life or job activities. Chronic pain and high-impact chronic pain both rose with age, with those aged 65 and above experiencing the most.

The global diclofenac patches market is segmented based on application and distribution channels. Based on application, the market is sub-segmented into lesions, sprains, and strains. Based on the distribution channel, the market is sub-segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Among these distribution channels, the retail pharmacy segment is expected to propel the growth of the market due to the increasing purchase of these patches from retail pharmacies for daily use especially to cure sprains.

The market players are also contributing significantly to the market’s growth by adopting various strategies, including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market.  For instance, in March 2019, Teva Pharmaceutical Industries Ltd. announced the launch of an authorized generic version of Flector1 Patch, 1.3 %, in the US. Diclofenac epolamine Topical Patch, 1.3%, an NSAID, is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Application
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Pfizer Inc., Cadila Healthcare Ltd., GlaxoSmithKline PLC, Hisamitsu Pharmaceutical Co. Inc., Novartis International AG, and Teva Pharmaceutical Industries Ltd. among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Diclofenac Patches Market Report by Segment

By Application

• Lesions
• Sprains
• Strains

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Diclofenac Patches Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa